90Y-Ibritumomab tiuxetan: new drug, interesting concept, and encouraging in practice.
Otte
Andreas
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology* / Q000532:radiotherapy*; D010818:Practice Patterns, Physicians' / Q000639:trends; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan